There's a new biomarker in the mix that could help diagnose patients at high risk for tuberculosis and lead to targeted treatments to combat it.
Here's why: The top 5 diagnostics-related venture capital deals in the 2014 second quarter are much more robust than those from the previous quarter, reflecting a larger med tech trend that produced a healthy hike in both deal value and volume versus Q1.
We all know the life sciences industry produces plenty of hype about new diagnostic advances, cutting-edge treatments and lifesaving surgeries. Many are profoundly amazing and life-changing inventions that have saved countless lives. But the truth is that much of patient diagnosis and care remains guesswork, trial, error and hope. Read more >>
POPULAR COMMENT THREADS
Illumina has inked deals with three major Big Pharma companies with a goal of developing a universal gene-sequencing companion diagnostic test system focused on cancer.
The FDA has signed off on a new, highly specific biomarker blood test designed by an Idaho company to quickly spot Type 1 diabetes.
Tissue-based companion diagnostics company Flagship Biosciences said it will join with Sarepta Therapeutics to automate and quicken measurement of a key biomarker for muscular dystrophy.
Roche's Ventana Medical Systems is building a new distribution center in Arizona and plans to generate additional jobs in the process.
GE Healthcare Life Sciences will locate its new U.S. headquarters in Marlborough, MA, hire at least 220 people and staff the facility with 500 employees.
A group of researchers from Thailand, the U.K. and elsewhere have developed a blood test that can identify people who have drug-resistant malaria.
From Our Sister Sites
Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.
Amazon is the latest tech giant to consider expanding into healthcare, but details of the online retailer's plans are sketchy.